Clinical efficacy of Dupilumab in the treatment of moderate to severe Atopic Dermatitis and Type-II Inflammation-Related comorbidities: A real-world study

Abstract

Objective: To evaluate real-world efficacy and safety of dupilumab in children and adults with moderate to severe atopic dermatitis (AD) combined with Type-II inflammatory diseases.

Methodology: A retrospective analysis was conducted on pediatric and adult AD patients treated with dupilumab at Renji Hospital (July 2021 to November 2023). Changes in medication scores, symptom severity and quality of life (QoL) assessments at three and six months were compared to baseline. Adverse events were monitored.

Results: All 33 patients demonstrated significant improvements in AD medication scores, symptoms and Qol at three/six months vs baseline. Efficacy at three months correlated with six months outcomes. The dupilumab regimen was associated with significantly improved symptoms of Type-II inflammatory comorbidities. Treatment was associated with symptoms that completely disappeared in 18.18% of AR patients and improved in 68.18% of AR cases. Of 11 FA patients, 90.90% reported symptom improvement. The dupilumab regimen led to a 100% and 20% prevalence of symptom improvement in chronic urticaria (CU) and AS patients, respectively, while 80% of AS patients reported complete disappearance of clinical symptoms. Among 15 AC patients, four (26.67%) had symptoms disappeared, seven (46.67%) improved. The dupilumab regimen led to symptom disappearance in one case of a patient with RS. Adverse effects of the treatment were mild.

Conclusion: Dupilumab is an effective and safe treatment for moderate-to-severe AD with Type-II inflammatory comorbidities, significantly improving clinical symptoms, reducing concomitant medication needs and enhancing QoL in real-world settings.